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facets. BDD, whether delusional or non-
delusional, responds to antidepressants, 
particularly SRIs. A recent double-blind trial 
comparing clomipramine with desipramine 
demonstrated the efficacy of the former 
irrespective of whether the patients had insight or 
held their dysmorphic perception with delusional 
intensity (Hollander etal., 1999). Moreover, there 
are reports of cases resistant to pimozide, the 
traditional choice for delusional BDD, subsequently 
responding to SRIs, which also happened in this 
patient (Wada et al., 1999). Thus the emerging 
consensus is that SRIs may be considered as 
first line agents in the treatment of BDD (Phillips 
etal., 1998; Hollander etal., 1999). 
An intriguing observation in our case was 
the non-response to one SRI and a subsequent 
response to another. Such a preferential response 
to one SRI over another has been cited before 
(Dominguez & Puig, 1997). Hence, a failed trial of 
one SRI should not deter a clinician from trying a 
second SRI. Augmenting with buspirone 
represents another alternative. Finally, another 
finding of significant clinical importance is that the 
presence of obsessive-compulsive symptoms, 
syndromal or otherwise, in BDD are not a pre-
requisite for response to SRIs considering that 
these agents have additional anti-obsessive 
properties and that BDD is an obsessive-
compulsive spectrum disorder (Hollander et al., 
1999). This too was adequately demonstrated by 
this report. 
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VENLAFAXINE - INDUCED ORTHOSTATIC 
HYPOTENSION 
Sir, 
Venlafaxine is a selective serotonin-
noradernaline reuptake inhibitor available in the 
Indian market in immediate and extended release 
(XR) preparations. Although dose-related 
hypertension is the commonly reported adverse 
effect of this drug with an incidence ranging form 
3 to 13 % depending on the dose (Beauclair et 
al., 2000), we describe a patient who developed 
unexpected orthostatic hypotension and had no 
underlying cardiac compromise 
P.T., a 46-year-old male diagnosed with 
treatment-resistant bipolar depression was started 
on venlafaxine-XR at a dose of 37.5 mg/day Then 
next dose hike was by 37.5 mg/day after four days 
with subsequent increase by 75 mg/day after a 
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week's interval till a dose of 225 mg/day. His base 
line blood pressure before commencing 
venlafaxine was 110/70 mmHg. At a dose of 225 
mg/day, the patient started experiencing episodes 
of severe dizziness on getting up and even had a 
fall on two occasions. Blood pressure record 
showed a significant postural drop from 100/70 
mmHg in the supine position to 50 mmHg systolic 
blood pressure with the diastolic component not 
recordable in the standing position. On reducing 
the dose of venalfaxine to 150 mg/day, there was 
a significant improvement in both the postural drop 
and the patient's subjective condition with the 
former remitting completely after a week of 
reducing venlafaxine. There was no dysfunction 
of other autonomic functions or cardiac abnormality 
or any other evidence to suggest any central 
nervous system pathology. A previous cranial CT 
scan showed mild cerebral atrophy but revealed 
no discernible cause for this postural drop. As he 
was on two drugs, venlafaxine-XR (225 mg/day) 
and valproate (600 mg/day) we speculated that 
either of these two or an interaction between these 
might have lead to the orthostatic hypotension. 
However, there was no evidence in literature to 
implicate valproate alone or in combination with 
venlafaxine for this presentation. As reduction in 
the dose of venlafaxine paralleled the improvement 
in orthostatic hypotension, it was tempting to 
speculate that venlafaxine may have caused this 
picture. Indeed, some evidence did emanate to 
support this contention. 
An EMBASE Psychiatry CD-ROM search 
using the key words 'orthostatic hypotension' and 
'venlafaxine' along with a manual search yielded 
few reports citing the existence of this adverse 
effect with venlafaxine. According to one source 
book on drugs, postural hypotension occurred in 
1 % out of 1033 subjects on venlafaxine as 
compared to nil out of 609 subjects on placebo 
(Facts and Comparison, 1998). Another study 
demonstrated unexpected orthostatic hypotension 
in 13 out of 18 patients who incidentally had some 
cardiac decompensation as well (Wiese & 
Alderman, 1999). In the same study, the 
orthostatic hypotension was more severe at the 
initiation of treatment and when the dose was 
increased, a finding concurring with ours in this 
patient. The rate of orthostatic hypotension with 
venlafaxine is comparable with rates seen with 
selective serotonin reuptake inhibitors (Feighner 
etal., 1994). The underlying mechanism for this 
adverse reaction of venlafaxine is speculative. 
Blocking of post-synaptic a 1 -adrenergic receptors, 
which is responsible for orthostatic hypotension, 
is minimal for venlafaxine in view of its 
considerably lower affinity than tricyclic 
antidepressants for binding with this receptor site 
(Holliday & Benfield, 1995). However, some 
binding with these receptors still occurs which 
may be idiosyncratically high in some patients 
resulting in a postural drop. 
Thus to conclude a clinician needs to bear 
in mind that venalfaxine, besides causing the 
usually known adverse effect of hypertension, can 
also lead to a significant orthostatic hypotension 
especially at higher doses. Whether this adverse 
affect is related to an underlying cardiac 
compromise or occurs idiosyncratically or is a 
harbinger of incipient dysautonomia needs to be 
addressed. 
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COMPULSIVE JOKING 
Sir, 
Compulsive rituals or acts are stereotyped 
behaviors that are neither enjoyable nor do they 
result in the completion of inherently useful tasks 
(World Health Organization, 1992). Herein we report 
a patient who presented to us with a rare 
compulsion of cutting jokes, a phenomenon which 
is unknown in the literature. 
A 32 year old male, well adjusted 
premorbidly, having no contributing past and family 
history, presented with a continuous illness of two 
years duration. To begin with, he started stealing 
things without reasons. When his father scolded, 
he told him that he had done it "just like that". 
Simulaneously, he also began spending more 
time in bathing as well as in religious rituals and 
started cutting jokes repeatedly. Every time he 
would tell the same set of 8-10 jokes at one go in 
a particular order. He would narrate the jokes in a • 
flat, monotonous voice as if it was a tidious, 
joyless chore. The jokes were inane and rather 
mirthless. He never seemed to draw pleasure or 
joy from telling the jokes. His face would appear 
tense and he seemed under a compulsion to finish 
an unpleasant task. Once initiated, he had to 
complete the entire set of jokes and felt very 
uneasy if the listener tried to escape. Rather, he 
would not allow the listeners to move until he had 
finished his stock of 8-10 jokes. He was hopeless, 
had no control of his behavior and was often 
ridiculed for it. Whenever he was asked the reason 
for cutting such flat jokes, the only answer used 
to be "just like that". 
Gradually within a year.all his unsuual 
behaviors except cutting jokes disappeared 
though he additionally developed overconcern 
about killing small insects and ants while walking 
and counting his steps while climbing and walking. 
Along wih this, he also became aloof and socially 
withdrawn. He had no depressive cognition or 
features suggestive of another psychiatric illness. 
On admission, because of his uncooperativeness, 
except stereotyped reeling out of jokes, no other 
psychopathology could be elicited. With the 
diagnosis of mania, treatment was initiated with 
trifluperazine 15 mg/day; however, he had no 
improvement with four weeks trial of trifluperazine. 
During subsequent examinations, he was found 
to have poor socialization, anxious affect, 
compulsion of cutting jokes with lack of control 
over the act and mounting inner tension when the 
act was prevented and intermittent third person 
auditory hallucinations. Following this, his 
diagnosis was changed to obsessive-compulsive 
disorder (OCD), with predominantly compulsions 
and paranoid schizophrenia (World Health 
Organisation, 1992). He did not improve with initial 
trials of fluoxetine 20-60 mg/day with haloperidol 
5 mg/day(three weeks) and ECT (six) with 
fluphenthixol 3-6 mg/day (two weeks). However, 
later on, after a month of combination therapy 
including clomipramine 75-150 mg/day, 
carbamazepine 600 mg/day and buspirone 1 mg/ 
day (augmentation) and olanzapine 10 mg/day, 
all his psychopathology but auditory hallucinations 
and withdrawn behaviour disappeared. At that time, 
he was discharged from the hospital and 
subsequently he was lost to follow-up. 
Although there are no previous reports and 
no obsession could be elicited, we considered 
cutting jokes as a compulsive phenomenon 
because the act of cutting jokes was repetitive, 
non-pleasurable, and uncontrollable and the 
subject felt mounting inner tension when he could 
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